Cost-Effectiveness of Oseltamivir and Favipiravir in Covid-19 Patients: a Cost-Effectiveness Analysis Study in a Hospital
Main Article Content
Abstract
The COVID-19 pandemic poses not only a threat to health but also to the global economy, including healthcare costs. Although there is no specific drug for COVID-19 patients, there are antiviral drugs such as oseltamivir and favipiravir that can be used to treat COVID-19. The purpose of this study was to determine the most cost-effective antiviral therapy between oseltamivir and favipiravir for COVID-19 patients in one of the hospitals in Banten province. The pharmacoeconomic method used in this study was cost-effectiveness analysis by calculating the Average Cost-Effectiveness Ratio (ACER) and Incremental Cost-Effectiveness Ratio (ICER). The results of this study showed that the ACER value of the favipiravir group (IDR 364,010 (n = 7)) was lower than the oseltamivir group (IDR 431,744 (n = 7)), with an ICER value of IDR 60,605. Based on the results of the Mann-Whitney test, there was no significant difference between the costs of the favipiravir and oseltamivir groups (p value 0.940). The sensitivity test showed that the cost of medical consumables was the cost that had the greatest impact on cost-effectiveness. Based on the calculation results, it can be concluded that the favipiravir group is more cost-effective than the oseltamivir group.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright and grant the journal the right of first publication simultaneously under the Creative Commons Attribution License. This license allows others to share the work with proper acknowledgment of authorship and initial publication in this journal. Authors are permitted and encouraged to deposit their articles in institutional repositories, on their personal websites, or in other online repositories after the article has been published in JSFK.
References
[1]. Kementrian Kesehatan Republik Indonesia, “Perkembangan COVID-19 di Indonesia Update tanggal 22 Juni 2020 Pukul 12.00 WIB,” 2020.
[2]. B. Sholehah, A. J. Gunawan, H. Siswanto, and H. F. Rahman, “Hubungan Kadar Saturasi Oksigen dengan Tingkat Kesembuhan Klien Corona Virus Disease-19 di Ruang Isolasi,” J. Penelit. Perawat Prof., vol. 4, no. 2, pp. 531–536, 2022, doi: 10.37287/jppp.v4i2.870.
[3]. CDC, “Coronavirus Disease 2019 (COVID-19) Situation,” vol. 2019.
[4]. Badan Pengawasan Obat dan Makanan Republik Indonesia, Informatorium obat Covid, 2nd ed. Jakarta: Badan Pengawasan Obat dan Makanan Republik Indonesia, 2020.
[5]. Kementrian Kesehatan RI, Pedoman Tatalaksana COVID-19, `3. Jakarta: Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter An, 2020.
[6]. Kementrian Kesehatan RI, Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/446/2020 Tentang Petunjuk Teknis Klaim Penggantian Biaya Pelayanan Pasien Penyakit Infeksi Emerging Tertentu Bagi Rumah Sakit Yang Menyelenggarakan Pelayanan Corona Virus Disease 2019 (C. 2020. [Online]. Available: https://wellness.journalpress.id/wellness/article/view/21026
[7]. Y. N. Patria and R. M. Sabirin, “COVID-19 potentially causes long-term deterioration of lung function: A systematic review and meta-analysis,” Med. J. Indones., vol. 30, no. 4, pp. 279–289, 2021, doi: 10.13181/mji.oa.215660.
[8]. Kementrian Kesehatan RI, Evaluasi Ekonomi dan Penilaian Teknologi Kesehatan. jaka: Kementerian Kesehatan RI, 2022.
[9]. Kementrian Kesehatan RI, Metodologi Penelitian. Jakarta: Kementerian Kesehatan RI, 2016.
[10]. S. Nurhayatun, N. Fitriyanti, and D. Sonia, “Analisis Average Length of Stay (Avlos) Kasus Covid-19 Di Rumah Sakit X Bandung,” J. Ilm. Mns. Dan Kesehat., vol. 4, no. 3, pp. 412–418, 2021, doi: 10.31850/makes.v4i3.988.
[11]. R. Adawiyah, T. Badriyah, and I. Syarif, “Hospital Length of Stay Prediction Based on Patient Examination Using Neural Network,” Klik - Kumpul. J. Ilmu Komput., vol. 8, no. 1, p. 28, 2021, doi: 10.20527/klik.v8i1.368.
[12]. E. Ndaparoka, O. Esther, and Y. Faot, “Kajian Literatur: Gambaran Lama Rawat Pasien Covid-19,” Universitas Pelita Harapan, 2021.
[13]. C. O. Tompodung, I. M. Sapulete, D. H. C. Pangemanan, and P. Korespondensi, “Gambaran Saturasi Oksigen dan Kadar Hemoglobin pada Pasien COVID-19,” eBiomedik, vol. 10, no. 1, pp. 35–41, 2022.
[14]. Y. A. Suwanto, L. Lusiana, and Y. Purnama, “Perbedaan Denyut Nadi dan Saturasi Oksigen Sebelum dan Sesudah Senam Bhineka Tunggal Ika (SBTI) di Era Pandemi Covid-19,” J. Sport Coach. Phys. Educ., vol. 6, no. 1, pp. 59–62, 2021, doi: 10.15294/jscpe.v6i1.46034.
[15]. C. Machado, P. A. Defina, Y. Machado, M. Chinchilla, and Y. Machado, “From happy or silent hypoxemia to acute respiratory syndrome in Covid-19 disease,” Cienciaworld.Com, no. July 2021, 2020, [Online]. Available: https://cienciaworld.com/from-happy-or-silent-hypoxemia-to-acute-respiratory-syndrome-in-Covid-19-disease.pdf
[16]. S. Dhont, E. Derom, E. Van Braeckel, P. Depuydt, and B. N. Lambrecht, “Conceptions of the pathophysiology of happy hypoxemia in COVID-19,” Respir. Res., vol. 22, no. 1, pp. 21–23, 2021, doi: 10.1186/s12931-021-01614-1.
[17]. M. Fathurrahman, A. Suwantika, and R. Hendriani, “ANALISIS EFEKTIVITAS BIAYA PROGRAM PENGELOLAAN PENYAKIT KRONIS (PROLANIS) TERHADAP PENYAKIT HIPERTENSI DI PUSKESMAS KOTA BANDUNG,” J. Sains dan Teknol. Farm. Indones., vol. 9, Oct. 2020, doi: 10.58327/jstfi.v9i1.131.
[18]. Y. Yusransyah, Y. Rahmawati, B. Udin, and N. M. Kurnia, “Cost-Effectiveness Analysis of Ceftriaxone and Cefixime in Typhoid Fever Patients Hospitalized At Berkah Pandeglang Regional Hospital for the Period 2020-2021,” J. Farm. Sains dan Prakt., vol. 9, no. 2, pp. 178–184, 2023, doi: 10.31603/pharmacy.v9i2.8648.
[19]. S. Cho, J. Hay, and A. Barzi, “Cost-Effectiveness Analysis of Regorafenib and Tas-102 In Refractory Metastatic Colorectal Cancer,” Value Heal., vol. 21, p. S1, 2018, doi: 10.1016/j.jval.2018.04.072.
[20]. S. Ikeme et al., “Cost-effectiveness analysis of a sealing hemostat patch (HEMOPATCH) vs standard of care in cardiac surgery,” J. Med. Econ., vol. 21, no. 3, pp. 273–281, 2018, doi: 10.1080/13696998.2017.1400977.
[21]. N. Tromp et al., “Cost-effectiveness of scaling up voluntary counselling and testing in West-Java, Indonesia,” Acta Med. Indones., vol. 45, no. 1, pp. 17–25, 2013.
[22]. B. K. Bellows, C. R. Tak, J. N. Sanders, D. K. Turok, and E. B. Schwarz, “Cost-effectiveness of emergency contraception options over 1 year,” Am J Obs. Gynecol, vol. 218, no. 5, pp. 1–18, 2018, doi: 10.1016/j.ajog.2018.01.025.Cost-effectiveness.
[23]. A. Paluseri, Fajriansyah, Zulfahmidah, and R. Oktaviani, “Analisis Efektivitas Biaya Penggunaan Antibiotik Levofloksasin Dan Azitromisin Pada Pasien Penderita Corona Virus Disease,” J. Farm., vol. XVII, no. 1, pp. 50–54, 2021.
[24]. W. R. Hidayani, “Faktor Faktor Risiko Yang Berhubungan Dengan COVID 19 : Literature Review,” J. Untuk Masy. Sehat, vol. 4, no. 2, pp. 120–134, 2020, doi: 10.52643/jukmas.v4i2.1015.
[25]. Kementrian Kesehatan RI, Pedoman Tatalaksana COVID-19 Edisi 4. 2022.
[26]. P. A. I. Ikasanti, R. Yulia, R. Hartono, P. S. Hanum, and F. Herawati, “Analysis of the Use of Antibiotics in Asymptomatic, Mild, and Moderate Covid-19 Patients Treated in Bhayangkara Hospital,” J. Berk. Epidemiol., vol. 10, no. 2, pp. 179–188, 2022, doi: 10.20473/jbe.v10i22022.179-188.
[27]. A. Berman et al., “Kozier and Erb’s Fundamentals of Nursing,” Kozier Erb’s Fundam. Nurs., p. 521, 2012.
[28]. Kementrian Kesehatan RI, Pedoman Penerapan Kajian Farmakoekonomi. Ja: Kementerian Kesehatan RI, 2013.
[29]. N. Nurmainah, S. Syabriyantini, and R. Susanti, “Efektivitas Biaya Penggunaan Ampisilin Dansefotaksim Pada Pasien Anak Demam Tifoid,” Media Kesehat. Masy. Indones., vol. 13, no. 2, p. 131, 2017, doi: 10.30597/mkmi.v13i2.1984.